Second, the persuit of cancer-related clinical trials for BET inhibitors [23–25, 35] suggests that Brd2 haploinsufficiency reduces cancer incidence in humans, just as our HET mice showed markedly reduced cancer incidence compared to WT (Table 3). Here, DNER is linked to cancer.